Skip to main content
Celltrion Pharm Inc. logo

Celltrion Pharm Inc. — Investor Relations & Filings

Ticker · 068760 ISIN · KR7068760008 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2025-12-30 Notice of Dividend Amou…
Country KR South Korea
Listing KO 068760

About Celltrion Pharm Inc.

https://www.celltrionph.com/en-us/home/…

Celltrion Pharm Inc. is a pharmaceutical company specializing in the manufacturing and supply of chemical pharmaceuticals and biosimilar products. The company's portfolio includes treatments for various conditions, with a notable focus on biosimilars for autoimmune diseases. A key product is Remsima, a biosimilar of Infliximab, indicated for treating rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis. As an integral part of the global biopharmaceutical company Celltrion, Celltrion Pharm distributes its products to both domestic and international markets, contributing to the accessibility of advanced biologic therapies.

Recent filings

Filing Released Lang Actions
[기재정정]현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a regulatory filing from Celltrion Pharm regarding a 'Decision on Cash/In-Kind Dividends'. It details the dividend amount per share, the total dividend amount, and the dividend yield, while also noting a correction to the previously filed dividend information. Since this document specifically announces the dividend amount and payment details for shareholders, it falls under the 'Notice of Dividend Amount' category.
2025-12-30 Korean
대규모기업집단현황공시[분기별공시(개별회사용)]
Governance Information Classification · 100% confidence The document is a 'Corporate Group Status Disclosure' (기업집단현황공시) filed by Celltrion Pharm. It details inter-company transactions, circular shareholding status, and financial guarantees within the Celltrion business group. These types of regulatory disclosures in South Korea are mandatory filings regarding corporate structure and governance, which do not fit into specific financial reporting categories like 10-K or IR, and are best classified as general regulatory filings.
2025-08-29 Korean
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
Regulatory Filings Classification · 100% confidence The document is a specific regulatory disclosure regarding payment methods, payment periods, and dispute resolution mechanisms under the Fair Transactions in Subcontracting Act (Article 13-3). It is a structured data filing submitted to a regulatory body (DART/KRX) rather than a general report or announcement. Since it does not fit into specific categories like financial reports, earnings, or governance, it falls under the general regulatory filing category.
2025-08-14 Korean
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for Celltrion Pharm, Inc. for the period ending June 30, 2025. It contains comprehensive financial data, management discussion and analysis, business operations, and governance information. As it is a comprehensive financial report for a period shorter than a full fiscal year (half-year) and contains actual financial statements and substantive data, it is classified as an Interim/Quarterly Report. H1 2025
2025-08-14 Korean
[기재정정]대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
Major Shareholding Notification Classification · 100% confidence The document is a 'Correction Report' (정정신고) for a 'Status Disclosure of Large Business Groups' (대규모기업집단현황공시). This is a mandatory regulatory filing in South Korea submitted to the Fair Trade Commission (FTC) or via the DART system. It details corporate governance, board operations, shareholding structures, and inter-company transactions. Since it does not fit into specific categories like 10-K, Earnings Release, or Proxy Statements, and is a formal regulatory disclosure, it is classified as a Regulatory Filing (RNS).
2025-06-23 Korean
대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
Major Shareholding Notification Classification · 100% confidence The document is a 'Corporate Group Status Disclosure' (기업집단현황공시) filed by Celltrion Pharm. This is a mandatory regulatory filing in South Korea under the Fair Trade Commission regulations, which requires large business groups to disclose company status, financial data, board composition, and internal transactions. Since it does not fit into specific categories like 10-K or Earnings Release, and is a formal regulatory disclosure document rather than a simple announcement of a report, it is classified as a Regulatory Filing (RNS).
2025-05-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.